Investors File Class Action Lawsuits Against Amylyx Pharmaceuticals Over ALS Treatment Claims

Allegations focus on misleading statements about RELYVRIO®'s commercial prospects, leading to significant stock price drop.

Investors have filed class action lawsuits against Amylyx Pharmaceuticals, Inc. (AMLX) following allegations of misleading statements regarding the commercial prospects of their ALS treatment, RELYVRIO®.
The lawsuits cover a class period from November 11, 2022, to November 8, 2023, with a lead plaintiff deadline set for April 9, 2024.
RELYVRIO®'s failure to meet primary and secondary endpoints in a Phase 3 trial led to a significant drop in Amylyx's stock price.
Allegations include overstating RELYVRIO®'s commercial prospects and prescription rate, and attempts to hide negative trends by blocking analysts from viewing prescription data.
Investors who suffered losses during the class period are urged to join the class action to potentially recover damages.